Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US And EU Systems For Personalized Medicine: Paths Diverging?

Executive Summary

There are changes afoot in the regulation and reimbursement policy for IVDs in the EU and US. When it comes to personalized medicine, and companion diagnostics in particular, are the two markets becoming more polarized? Medtech Insight asked US- and EU-based attorneys at Hogan Lovells.

You may also be interested in...



Could EU's New HTA Proposal Promote EU-Wide Reimbursement Of Personalized Medicine?

Personalized medicine has yet to really take off in the EU. One of the main barriers are the fragmented rules around reimbursement. Could the European Commission's health technology assessment proposal help?

Labs, Test Makers Urge Congress To Pass Diagnostic Reforms

More than 80 industry, laboratory, health-care provider and patient groups sent a letter to two congressional committees, urging them to advance a bill to modernize the current way FDA regulates diagnostic tests, including possibly a new regulated product category that combines laboratory developed tests and in vitro diagnostics.

Medicare Finalizes NGS Test Coverage For Advanced Cancers, Drops Evidence-Collection Provision

The US Centers for Medicare and Medicaid Services said on March 16 that it will cover next-generation sequencing diagnostic laboratory tests for advanced cancers, broadening its final determination to cover use in relapsed, refractory and stage III cancers, while dropping "coverage with evidence development" conditions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel